STING (or SRC) Like an ICB: Priming the Immune Response in Pancreatic Cancer

Area of Science:

• Oncology
• Immunology
• Cancer Research

Background:

• Pancreatic adenocarcinoma presents a poor prognosis and resistance to immune checkpoint blockade therapies.
• Understanding mechanisms to overcome immune evasion in pancreatic cancer is critical for developing effective treatments.

Purpose of the Study:

• To investigate the role of ataxia telangiectasia mutated (ATM) in pancreatic cancer immune response.
• To evaluate the potential of combining ATM inhibition with other therapies to enhance anti-tumor immunity.

Main Methods:

• Pharmacologic blockade and siRNA silencing of ATM in pancreatic cancer models.
• Assessment of type I Interferon (IFN) signaling pathways (cGAS/STING-independent, SRC-dependent).
• Combination therapy including ATM inhibition, radiotherapy, and PD-L1 blockade in vivo.

Main Results:

• ATM inhibition increases type I IFN release in pancreatic cancer models.
• Combination of ATM inhibition and radiotherapy amplifies type I IFN signaling, PD-L1 expression, and tumor-infiltrating immune cells (CD8+ T cells, proinflammatory macrophages).
• Combined ATM silencing, radiotherapy, and PD-L1 blockade significantly improves murine tumor responses.

Conclusions:

• Inhibition of ATM-mediated DNA repair represents a viable strategy to enhance anti-tumor immunity in pancreatic cancer.
• The combination of ATM inhibition, radiotherapy, and PD-L1 blockade demonstrates significant therapeutic potential for pancreatic adenocarcinoma.
• Further clinical investigation of this multi-modal approach is warranted for pancreatic cancer treatment.